Abstract:Background: Lymphoma is a common malignant proliferative disease in which bone marrow infiltration will upstage the disease and thus affect prognosis of the disease. As of now bone marrow biopsy is considered as a reference standard to find out bone marrow involvement in lymphoma. Performing an invasive and painful intervention in all newly diagnosed lymphoma patients is controversial. PET-CT is a non-invasive technique that gives functional information about the cells using the glucose metabolism. It can detect early bone marrow and extra medullary organ involvement which can lead to restaging of the disease. These advantages make PET-CT a valuable adjunct in diagnosis of lymphoma. Aims and objectives: Our study aims to evaluate the usefulness of 18 F-FDG PET-CT, a non-invasive, semi quantitative whole body imaging technique for detection of early bone marrow and extra medullary organ involvement in lymphoma patients which in turn can obviate the need for bone marrow study (BMS). The primary objective of study is to categorise FDG uptake in bone marrow as diffuse /unifocal /multifocal / no uptake and to correlate pattern of FDG uptake to bone marrow study. Our study also assesses the role of FDG PET/CT in staging of lymphoma. Materials and methods: Thirty patients with newly diagnosed lymphoma in the age group 18 to 75 years of both sexes within 3 months of diagnosis and who have not been started on any treatment was included in the study. Marrow uptake on FDG PET/CT has been categorized as diffuse, unifocal, multifocal and no uptake. Agreement between bone marrow study and FDG PET/CT has been assessed by reliability analysis using Cohen's kappa. Sensitivity, specificity, PPV, NPV of PET/CT in detecting marrow involvement have been calculated. Results: The sensitivity, specificity, PPV, NPV and accuracy of 18 F-FDG PET-CT in detecting marrow involvement of lymphoma cases are 86.6%, 77.7%, 68.4%, 91.3% and 80.9% respectively. 18 F-FDG PET-CT detected bone marrow involvement in 86.6% (13 out of 15 total positive cases) cases of lymphoma which included both HL and NHL. Reliability analysis using Cohen's kappa is used to test the agreement between bone marrow study and 18F-FDG PET/CT. k value of 0.6 was obtained which showed a moderate agreement between bone marrow study and 18F-FDG PET/CT in marrow assessment. Conclusion: 18F-FDG PET/CT is a highly sensitive imaging modality which can pick up extra-nodal organ and BMI in patients with lymphoma and can upstage the disease and alter treatment strategies. PET-CT cannot completely replace the bone marrow study. However, being an invasive painful procedure, BMB can be avoided in cases with unifocal or multifocal marrow involvement on PET-CT.

The role of 18F-FDG PET/CT in Neurolymphomatosis: A Comprehensive Imaging Approach

Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases

18F-FDG PET/CT in Histiocytic Necrotizing Lymphadenitis:Two Cases and Review of the Literature

The Role Of 18F-FDG PET/CT In Evaluation Of Primary CNS Lymphoma: The Path Less Travelled

Role Of F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography In Patients With Nasal-Type Natural Killer T-Cell Lymphoma

Positron Emission Tomography/computed Tomography in the Diagnosis, Staging, and Prognostic Evaluation of Natural Killer/t-Cell Lymphoma.

Role Of Pet/Ct In The Diagnosis, Staging, And Follow-Up Of A Nasal-Type Natural Killer T-Cell Lymphoma In The Larynx: A Case Report And Literature Review

Analysis of 18F-FDG PET/CT Imaging Features of Neurolymphomatosis

Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma

Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI

Research progress in the diagnostic application of FDG PET/CT imaging in paraneoplastic neurological syndromes

The key role of 18F-FDG PET/CT for correct diagnosis, staging, and treatment in a patient with simultaneous NPC and TB lymphadenitis: case report

Enhancing Prognostication and Treatment Response Evaluation in Primary CNS Lymphoma with 18F-FDG PET/CT

Primary central nervous system lymphoma: advances in MRI and PET imaging

18F-FDG PET/CT in Immunocompetent Patients with Primary Central Nervous System Lymphoma: Differentiation from Glioblastoma and Correlation with DWI.

Preliminary application of 18F-FDG PET/CT in cutaneous lymphoma

Role of 2-(fluorine-18) Fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography in Initial Staging and Bone Marrow Involvement Prediction in Patients with Newly Diagnosed Lymphoma in Correlation with Bone Marrow Study

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas

<SUP>18</SUP>F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method

Bios-03. Clinical Presentation, Management, And Outcome In Neurolymphomatosis: A Systematic Review And Analysis Of Individual Patient Data From 459 Cases

18F-FDG PET/MR for diagnosis of primary central nervous system lymphoma: protocol for a systematic review and meta-analysis